Chemotherapy-associated lipid changes in breast cancer patients: A retrospective analysis from a high-volume institution in China.

Abstract

e12039 Background: Cytotoxic treatment may cause alterations in serum lipid of breast cancer patients but it remains controversial yet. The aim of this study is to investigate status of serum lipid pre- and post-chemotherapy as well as to compare lipid level alterations between different chemotherapy modalities. Methods: We retrospectively identified 1934 consecutive female patients who were surgically treated and pathologically diagnosed as breast cancer from February 2009 to December 2016 in a single institution. Results: There were 483(24.97%), 484(25.03%), 467(24.15%) and 500(25.85%) patients received AC-T, EC-T, TC and FEC chemotherapy regiment respectively. For the entire cohort, the levels of TG, TC and LDL were significant elevated in patients who received chemotherapy ( p＜ 0.01) while no significant difference was observed for HDL between pre- and post-chemotherapy. With chemotherapy regimens stratification, there were statistical significances with respect to TG, TC, HDL and LDL in AC-T, TC and FEC group between pre- and post-chemotherapy respectively ( p ＜0.05). Breast cancer patients with AC-T chemotherapy regimen increased TG value was higher than that of EC-T, TC, FEC regimens ( p ＜0.001) in premenopausal group. Moreover, utilizing of FEC regimen was associated with a significantly increased lipid level of HDL compared with the remaining regimens for both premenopausal and postmenopausal patients. Conclusions: Breast cancer patients receiving chemotherapy may carry a high risk of dyslipidemia. Therefore, regular lipid monitoring is very necessary for those breast cancer patients who receiving chemotherapy postoperatively.